Literature DB >> 4143315

Treatment of parkinsonism with bromocriptine.

D B Calne, P F Teychenne, P N Leigh, A N Bamji, J K Greenacre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4143315     DOI： 10.1016/s0140-6736(74)92219-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  35 in total

Review 1.  Bromocriptine for levodopa-induced motor complications in Parkinson's disease.

Authors:  J J van Hilten; C Ramaker; W J Van de Beek; M J Finken
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Editorial: Bromocriptine--a changing scene.

Authors: 
Journal:  Br Med J       Date:  1975-12-20

4.  Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors.

Authors:  Dongim Cho; Mei Zheng; Chengchun Min; Lan Ma; Hitoshi Kurose; Jae H Park; Kyeong-Man Kim
Journal:  Mol Endocrinol       Date:  2010-02-16

5.  Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation.

Authors:  Scoty M Hearst; Mariper E Lopez; Qingmei Shao; Yong Liu; Parminder J S Vig
Journal:  J Neurochem       Date:  2010-04-30       Impact factor: 5.372

6.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

7.  ARF6 and GASP-1 are post-endocytic sorting proteins selectively involved in the intracellular trafficking of dopamine D₂ receptors mediated by GRK and PKC in transfected cells.

Authors:  D I Cho; M Zheng; C Min; K J Kwon; C Y Shin; H K Choi; K M Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.

Authors:  Yang Yang; Kenza Mamouni; Xin Li; Yanhua Chen; Sravan Kavuri; Yuhong Du; Haian Fu; Omer Kucuk; Daqing Wu
Journal:  Mol Cancer Ther       Date:  2018-06-15       Impact factor: 6.261

9.  Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine.

Authors:  M T Hyyppä; V A Långvik; U K Rinne
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.